Amneal Pharmaceuticals (AMRX) Other Non Operating Income (2017 - 2026)

Amneal Pharmaceuticals' Other Non Operating Income history runs 10 years deep, the most recent figure standing at -$3.5 million for Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 182.65% year-over-year to -$3.5 million in Q1 2026; TTM through Mar 2026 was -$706000.0, a 108.2% decrease from a year earlier, with the FY2025 full-year figure at -$31.4 million, changed N/A from the prior year.
• Other Non Operating Income declined to -$3.5 million in Q1 2026 per AMRX's latest filing, from -$35000.0 in the prior quarter.
• Across five years, Other Non Operating Income topped out at $6.9 million in Q2 2022 and bottomed at -$15.1 million in Q4 2022.
• The 5-year median for Other Non Operating Income is $1.2 million (2025), against an average of -$12200.0.
• Across the five-year window, Other Non Operating Income tumbled 18834.48% in 2022 and soared 945.56% in 2024, its largest moves.
• Year by year, Other Non Operating Income stood at -$15.1 million in 2022, then jumped by 110.8% to $1.6 million in 2023, then soared by 167.98% to $4.4 million in 2024, then plunged by 100.8% to -$35000.0 in 2025, then tumbled by 9928.57% to -$3.5 million in 2026.
• Per Business Quant, the three latest AMRX Other Non Operating Income figures stand at -$3.5 million (Q1 2026), -$35000.0 (Q4 2025), and $1.2 million (Q3 2025).